{"gene":"LAMB3","run_date":"2026-06-10T02:59:49","timeline":{"discoveries":[{"year":1994,"finding":"Homozygous nonsense mutations (premature termination codons) in LAMB3, encoding the β3 chain of laminin 5, cause complete absence of laminin 5 protein and result in Herlitz junctional epidermolysis bullosa (H-JEB), establishing LAMB3 as essential for laminin 5 assembly and dermal-epidermal adhesion.","method":"Northern hybridization, RT-PCR, direct nucleotide sequencing of keratinocyte mRNA, genomic DNA verification","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct mutation identification with mRNA and protein consequence, replicated across many subsequent studies","pmids":["7698759"],"is_preprint":false},{"year":1995,"finding":"The human LAMB3 gene consists of 23 exons spanning ~29 kb, encoding 1172 amino acids; its exon-intron organization is more compact than LAMB1, and this structure was used to establish the molecular basis of JEB mutations.","method":"Characterization of overlapping lambda phage DNA clones, sequencing of exon-intron boundaries, comparison with LAMB1 gene structure","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1 / Strong — complete gene structure determined by direct sequencing, foundational structural characterization","pmids":["7774918"],"is_preprint":false},{"year":1995,"finding":"Mutations in LAMB3 exons 3 and 7 (encoding part of domain VI of the β3 chain short arm) cause generalized atrophic benign epidermolysis bullosa; the domain VI globular domain is postulated to mediate interaction of laminin 5 with laminin 6 (K-laminin), and its disruption reduces epidermal-dermal adhesion.","method":"PCR amplification of genomic DNA, heteroduplex analysis, nucleotide sequencing, immunofluorescence and immunoelectron microscopy, transmission electron microscopy","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — mutation identified with protein-level consequence validated by immunofluorescence and electron microscopy","pmids":["7706760"],"is_preprint":false},{"year":1995,"finding":"TGF-β upregulates LAMB3 gene expression in human epidermal keratinocytes (as well as HaCaT and Balb/K cells), whereas TNF-α alone does not alter LAMB3 expression; the three laminin 5 subunit genes (LAMA3, LAMB3, LAMC2) are not coordinately regulated by these cytokines.","method":"Northern hybridization with specific cDNA probes, cytokine treatment of cultured keratinocytes","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Northern hybridization in multiple cell lines, single lab, consistent across cell types","pmids":["7635220"],"is_preprint":false},{"year":1996,"finding":"Two recurrent nonsense mutations in LAMB3, R42X and R635X (at CpG dinucleotides), account for over 50% of mutant LAMB3 alleles in H-JEB families; haplotype analysis demonstrated R635X arose on different genetic backgrounds, confirming CpG hypermutability as a mechanism.","method":"PCR, restriction enzyme digestion, haplotype analysis with intragenic polymorphisms, pedigree analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated across 14 families, haplotype analysis confirming independent mutational events","pmids":["8824879"],"is_preprint":false},{"year":1997,"finding":"Insertion of an intracisternal-A particle (IAP) into the LamB3 coding sequence in mice abolishes LamB3 mRNA and laminin-5 protein expression, causing sub-epithelial blisters and abnormal hemidesmosomes lacking sub-basal dense plates, establishing a functional role for laminin-5/LAMB3 in hemidesmosome formation.","method":"Linkage analysis, Northern blot, immunohistochemistry, DNA sequence analysis of IAP insertion site, transmission electron microscopy","journal":"Mammalian genome","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo loss-of-function model with defined ultrastructural phenotype, multiple orthogonal methods","pmids":["9271670"],"is_preprint":false},{"year":1998,"finding":"A missense mutation E210K (628G→A) at the last nucleotide of LAMB3 exon 7 causes both an amino acid substitution and aberrant splicing, generating multiple aberrant mRNA species and reduced expression of laminin 5 with altered biological activity, resulting in a mild (non-lethal) JEB phenotype.","method":"RT-PCR analysis of aberrant splice variants, sequencing, mRNA decay analysis, immunofluorescence","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — mutation characterized at both mRNA and protein levels with multiple orthogonal methods","pmids":["9501007"],"is_preprint":false},{"year":1998,"finding":"The LAMB3 missense mutation E210K in compound heterozygosity with a nonsense mutation is predictive of generalized atrophic benign EB phenotype; the combination of a null allele and E210K allows reduced expression of a partly functional laminin 5 protein.","method":"PCR, heteroduplex analysis, direct sequencing, genotype-phenotype correlation across three patients","journal":"The British journal of dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genotype-phenotype correlation confirmed in three independent patients, single method (sequencing)","pmids":["9767254"],"is_preprint":false},{"year":1998,"finding":"A LAMB3 frameshift mutation (1367delAC) causes accelerated mRNA decay, rendering the transcript undetectable by RT-PCR; a missense mutation (C293S) in the other allele results in reduced laminin 5 expression in generalized atrophic benign EB.","method":"Heteroduplex scanning, direct automated sequencing, RT-PCR for mRNA stability assessment","journal":"Laboratory investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — mRNA consequences of specific mutations directly characterized, two orthogonal methods","pmids":["9690563"],"is_preprint":false},{"year":1999,"finding":"Digenic JEB can result from mutations in both COL17A1 and LAMB3: compound heterozygous COL17A1 null mutations combined with one LAMB3 null allele (R635X heterozygosity) causes absence of collagen XVII and attenuated laminin 5 expression, rudimentary hemidesmosome structure, and severe blistering—demonstrating functional interaction between these two hemidesmosome-anchoring filament complex proteins.","method":"Mutation analysis by sequencing, immunofluorescence of skin, electron microscopy of hemidesmosome structure","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — epistatic interaction between two genes confirmed by protein expression and ultrastructural analysis","pmids":["10577906"],"is_preprint":false},{"year":2004,"finding":"A synonymous LAMB3 variant (3009C→T in exon 20) creates a novel exonic splice site that is preferentially used by the spliceosome over the wild-type splice site despite having a lower splice score (68.6 vs. 92.2); the resulting aberrant mRNA leads to a stop codon in exon 21 and undergoes allele-specific nonsense-mediated mRNA decay.","method":"DNA sequencing, RT-PCR analysis of splice variants, computational splice-site scoring, immunohistochemistry/immunoelectron microscopy","journal":"Laboratory investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — splicing mechanism directly characterized at mRNA level with computational validation and functional consequence","pmids":["15311214"],"is_preprint":false},{"year":2006,"finding":"Prenatal delivery of LAMB3 cDNA via adenoviral and AAV vectors to laminin-5 β3-deficient mice showed that the transgenic β3 chain assembles with endogenous partner chains (α3 and γ2) to produce laminin-5, which deposits in basement membranes of skin and mucosae, reducing tissue separation—demonstrating that LAMB3/β3 chain is a limiting subunit for laminin-5 trimer assembly.","method":"In vivo prenatal gene delivery, immunohistochemistry for laminin-5, co-assembly assessment in basement membranes of H-JEB mice","journal":"Gene therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo reconstitution of trimer assembly, single study with partial therapeutic rescue","pmids":["16871230"],"is_preprint":false},{"year":2007,"finding":"Multiple distinct second-site mutations in LAMB3 can correct the germline E210K mutation in vivo (revertant mosaicism), restoring laminin-332 expression in naturally corrected keratinocytes; different correcting mechanisms (splice site alterations, missense changes) all restored normal laminin-332, confirming the necessity of intact LAMB3 for laminin-332 assembly.","method":"DNA analysis of revertant keratinocytes from multiple biopsy specimens, immunofluorescence for laminin-332, sequencing of second-site mutations","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple independent revertant events confirmed by sequencing and protein expression, natural in vivo experiment","pmids":["17476356"],"is_preprint":false},{"year":2011,"finding":"LAMB3 expression in gastric cancer is regulated epigenetically: promoter demethylation (DNA hypomethylation) is associated with LAMB3 upregulation, and the active histone mark H3K4me3 is associated with its expression; treatment with a methylation inhibitor induces LAMB3 expression in silenced cell lines.","method":"Combined DNA methylation and gene expression analysis, chromatin immunoprecipitation (ChIP) assay for H3K4me3, methylation inhibitor treatment","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus methylation inhibitor experiments, single lab, two orthogonal methods","pmids":["21345334"],"is_preprint":false},{"year":2013,"finding":"Knockdown of LAMB3 suppresses invasion and metastasis of lung cancer cells in vitro and in vivo, establishing a functional role for LAMB3 in cancer cell invasive behavior.","method":"siRNA and lentiviral shRNA knockdown, invasion/migration assays in vitro, in vivo tumor metastasis models","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined cellular and in vivo phenotypes, single lab","pmids":["23441154"],"is_preprint":false},{"year":2016,"finding":"miR-1298 inhibits KRAS-driven cancer cell growth by directly targeting LAMB3 (and FAK); silencing LAMB3 alone recapitulates the synthetic lethal effect of miR-1298, while co-expression of LAMB3 and FAK rescues miR-1298-induced cell death, placing LAMB3 downstream of mutant KRAS signaling.","method":"miR-TRAP affinity purification to identify LAMB3 as miR-1298 target, siRNA knockdown, rescue co-expression experiments, in vivo tumor growth assays","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — miR-TRAP affinity purification to identify target, validated by knockdown and rescue experiments in vitro and in vivo","pmids":["27698189"],"is_preprint":false},{"year":2018,"finding":"Gentamicin induces readthrough of LAMB3 premature termination codons (including R635X and C290X) in H-JEB keratinocytes, producing full-length laminin β3 in a dose-dependent manner; this restored laminin 332 assembly, secretion, deposition at the dermal-epidermal junction, proper α6β4 integrin polarization, and corrected abnormal cell morphology, poor growth, poor adhesion, and hypermotility.","method":"Transfection of expression vectors with 8 different LAMB3 nonsense mutations, lentiviral stable transduction, gentamicin treatment, immunoblot, immunofluorescence, 3D skin equivalent model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — functional reconstitution of full laminin 332 assembly with multiple orthogonal methods and 8 different mutations tested","pmids":["29946029"],"is_preprint":false},{"year":2018,"finding":"LAMB3 suppression in papillary thyroid cancer reduces cell migration and invasion via downregulation of EMT-associated proteins (N-cadherin, vimentin, slug) and inhibition of MMP9; LAMB3 inhibition also significantly decreases AKT phosphorylation and inhibits c-MET transcription, indicating LAMB3 promotes invasion via the HGF/c-MET/AKT axis.","method":"siRNA knockdown, migration/invasion assays, Western blot for EMT markers, AKT phosphorylation, and c-MET","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with multiple downstream signaling readouts, single lab","pmids":["29426928"],"is_preprint":false},{"year":2018,"finding":"CRISPR/Cas9-mediated HDR using an adenovector (Cas9/gRNA targeting intron 2) and an integration-defective lentiviral vector (promoterless LAMB3 cDNA with splice acceptor) restores monoallelic LAMB3 expression in JEB keratinocytes; monoallelic correction was sufficient to restore adhesion, colony formation, and normal dermal-epidermal junction in skin equivalents transplanted onto immunodeficient mice.","method":"CRISPR/Cas9 HDR gene correction, in vitro adhesion and colony formation assays, in vivo skin equivalent grafting","journal":"Molecular therapy","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution of function by precise gene correction with in vitro and in vivo validation","pmids":["30122422"],"is_preprint":false},{"year":2019,"finding":"LAMB3 inhibition in pancreatic ductal adenocarcinoma cells abrogates PI3K/AKT pathway activation, causing cell cycle arrest and apoptosis, and reduces proliferation, invasion, migration, tumor growth, and liver metastasis in vivo.","method":"siRNA knockdown, cell cycle analysis, apoptosis assays, invasion/migration assays in vitro, xenograft and liver metastasis models in vivo, Western blot for PI3K/AKT pathway","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with in vitro and in vivo phenotypes plus signaling pathway readout, single lab","pmids":["30850586"],"is_preprint":false},{"year":2020,"finding":"LAMB3 transcription in colorectal cancer is directly regulated by the BRD2/acetylated-ELK4 complex: ELK4 (acetylated at K125) cooperates with BRD2 to bind ETS motifs in the LAMB3 promoter; BET inhibitor JQ1 disrupts the ELK4-BRD2 interaction and reduces BRD2 binding to the LAMB3 promoter, downregulating LAMB3. Downstream, LAMB3 activates AKT to inhibit FOXO3/4 tumor-suppressive function.","method":"ChIP assay, luciferase reporter assays for promoter binding, Co-IP for ELK4-BRD2 interaction, JQ1/U0126 inhibitor treatment, Western blot, in vitro and in vivo tumor models","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct promoter binding confirmed by ChIP, protein interaction by Co-IP, functional readout with inhibitors, multiple orthogonal methods in single study","pmids":["32398865"],"is_preprint":false},{"year":2020,"finding":"miR-24-3p directly targets the LAMB3 3'UTR to suppress LAMB3 expression in pancreatic ductal adenocarcinoma cells; overexpression of miR-24-3p inhibits PDAC proliferation, cell cycle progression, and invasion by suppressing LAMB3, and this was confirmed in a xenograft model.","method":"Dual-luciferase reporter assay targeting LAMB3 3'UTR, FISH for subcellular localization of miR-24-3p and LAMB3 mRNA, rescue assays, subcutaneous xenograft","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct 3'UTR targeting confirmed by luciferase assay plus rescue experiments, single lab","pmids":["32039003"],"is_preprint":false},{"year":2022,"finding":"S100A10 activates LAMB3 expression through the JNK pathway in pancreatic ductal adenocarcinoma; LAMB3 was shown to physically interact with LAMC2, and LAMB3 mediates the effects of S100A10 on cell proliferation, migration, and adhesion.","method":"RNA-sequencing, Western blotting, co-immunoprecipitation for LAMB3-LAMC2 interaction, JNK pathway inhibition, knockdown/overexpression rescue experiments, orthotopic tumor model","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for LAMB3-LAMC2 interaction plus signaling pathway rescue experiments, single lab","pmids":["36612197"],"is_preprint":false},{"year":2022,"finding":"PIGR physically associates with the transcriptional repressor REST and blocks REST-mediated transcription of LAMB3 in colorectal cancer; PIGR overexpression downregulates LAMB3, suppressing the AKT-FOXO3/4 axis and inhibiting CRC cell malignant phenotypes.","method":"Co-immunoprecipitation of PIGR-REST complex, Western blot, in vitro functional assays, in vivo xenograft","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for PIGR-REST interaction, LAMB3 as downstream target, functional readout, single lab","pmids":["35992840"],"is_preprint":false},{"year":2023,"finding":"LAMB3 promotes intestinal inflammation through upregulation of SERPINA3 via the integrin α3β1/FAK pathway; NF-κB (P65) directly transcriptionally activates LAMB3 under TNF-α stimulation, as demonstrated by dual-luciferase assays and ChIP-PCR.","method":"Dual-luciferase assay, ChIP-PCR, RNA-sequencing, qRT-PCR, Western blotting, NF-κB inhibitor treatment","journal":"Inflammatory bowel diseases","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct transcriptional regulation confirmed by ChIP-PCR and luciferase assays, downstream pathway by RNA-seq and rescue, multiple orthogonal methods","pmids":["37454278"],"is_preprint":false},{"year":2023,"finding":"LAMB3 knockdown in nasopharyngeal carcinoma cells promotes apoptosis and reduces radioresistance by enhancing FOXO3 expression and thereby deactivating the NRF2 signaling pathway, leading to increased ROS accumulation after X-ray treatment.","method":"shRNA knockdown, ROS measurement, Western blot for NRF2/FOXO3 pathway, rescue experiments with NRF2 suppression, in vivo xenograft irradiation model","journal":"Journal of radiation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with downstream pathway rescue, confirmed in vivo, single lab","pmids":["36947579"],"is_preprint":false},{"year":2023,"finding":"LAMB3 promotes myofibrogenesis and cytoskeletal reorganization in endometrial stromal cells via the RhoA/ROCK1/MYL9 pathway; LAMB3 overexpression promotes TGF-β-induced myofibroblast phenotype conversion and actin cytoskeleton remodeling, while LAMB3 silencing reverses these effects, and both are abrogated by the ROCK inhibitor Y-27632 or the RhoA activator LPA.","method":"LAMB3 overexpression and knockdown in primary endometrial stromal cells, PCR, Western blot, phalloidin staining for actin cytoskeleton, pharmacological inhibition/activation of RhoA/ROCK pathway","journal":"Cell biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with pharmacological pathway manipulation, two orthogonal methods, single lab","pmids":["37801199"],"is_preprint":false},{"year":2024,"finding":"NAT10 enhances LAMB3 mRNA stability via N4-acetylcytidine (ac4C) modification of LAMB3 mRNA; stabilized LAMB3 then activates the FAK/ERK pathway to promote PDAC tumor progression and upregulate PD-L1 expression, reducing CD8+ T cell cytotoxicity.","method":"Acetylated RNA immunoprecipitation (acRIP), qPCR, RNA immunoprecipitation, Western blotting, single-cell RNA sequencing, multiplexed immunofluorescence, flow cytometry, in vivo mouse models","journal":"Cancer communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct mRNA modification identified by acRIP, downstream FAK/ERK signaling confirmed by Western blot, multiple orthogonal methods","pmids":["40540648"],"is_preprint":false},{"year":2024,"finding":"FOXQ1, stabilized by PARP1 (via inhibition of E3 ubiquitin ligase CHIP-mediated degradation), directly binds the LAMB3 promoter region to activate LAMB3 transcription, which in turn activates the WNT/β-catenin signaling pathway to promote ovarian cancer progression.","method":"Co-IP, mass spectrometry, ubiquitination assays, ChIP-seq, ChIP-PCR, luciferase assays, RNA-seq, GSEA, Western blot, in vivo animal models","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct promoter binding by ChIP-seq/ChIP-PCR, PARP1-FOXQ1 interaction by Co-IP and MS, ubiquitination mechanism characterized, multiple orthogonal methods","pmids":["38297082"],"is_preprint":false},{"year":2024,"finding":"MDFI directly interacts with LAMB3 (and ITGB4) in colorectal cancer cells, as confirmed by co-immunoprecipitation; MDFI upregulates the AKT pathway via its binding to LAMB3/ITGB4, enhancing CRC cell proliferation and reducing sensitivity to oxaliplatin and fluorouracil.","method":"Single-cell RNA sequencing, co-immunoprecipitation for MDFI-LAMB3/ITGB4 interaction, knockdown and lentiviral overexpression, Western blot, colony formation and CCK-8 assays","journal":"Cancer biology & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP confirming direct LAMB3-MDFI interaction, functional pathway activation, single lab","pmids":["38375821"],"is_preprint":false},{"year":2024,"finding":"LAMB3 mediates gemcitabine resistance in PDAC through a YAP-LAMB3 feedback axis: YAP activates LAMB3 transcription via TEAD4, and LAMB3 in turn amplifies YAP signaling; this axis drives epithelial-mesenchymal transition and Gem resistance.","method":"Knockdown and overexpression experiments, in vitro drug sensitivity assays, Western blot for YAP/TEAD4/EMT markers, in vivo xenograft model","journal":"Molecular carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain/loss-of-function establishing feedback loop, drug resistance phenotype validated in vivo, single lab","pmids":["39016677"],"is_preprint":false},{"year":2024,"finding":"LAMB3 knockdown decreases CXCL2 expression, reduces cancer-associated fibroblast (CAF) infiltration, and increases olaparib sensitivity in triple-negative breast cancer; melatonin downregulates LAMB3, and the LAMB3-CXCL2 axis was found to collaboratively promote CAF infiltration and immunosuppression.","method":"RNA-sequencing, genetic ablation (LAMB3 knockdown), Western blot, in vivo tumor models with combination treatment, immune cell profiling","journal":"Pharmacological research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq plus loss-of-function with downstream CXCL2 and immune phenotype, in vivo validation, single lab","pmids":["39306019"],"is_preprint":false},{"year":2024,"finding":"CRABP2 upregulates LAMB3 mRNA and protein expression (shown by RNA-seq and Western blot), and LAMB3 in turn activates the PI3K/AKT and MAPK signaling pathways to promote cell migration and invasion in prostate cancer.","method":"RNA-seq after CRABP2 overexpression, Western blot for LAMB3 and downstream pathway proteins, migration/invasion assays, in vivo tumor model","journal":"Journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq identification with Western blot validation, downstream signaling confirmed, single lab","pmids":["39038078"],"is_preprint":false},{"year":2024,"finding":"An intronic LAMB3 variant (c.-38+2 T>C) activates a cryptic splice site, causing 120 bp intronic inclusion in the 5'UTR; this creates upstream AUGs and uORFs and a more complex 5'UTR secondary structure, significantly reducing translation efficiency of LAMB3 without affecting overall mRNA levels, causing JEB.","method":"Whole-exome and whole-genome sequencing, luciferase translational efficiency assays, splice assay (minigene), in silico structural analysis, RT-PCR on patient gingival sample","journal":"Archives of oral biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — translational mechanism directly characterized by luciferase assay, splice mechanism by minigene assay, patient sample validation, multiple orthogonal methods","pmids":["39357391"],"is_preprint":false},{"year":2025,"finding":"TGF-β secreted by hypoxic renal tubular epithelial cells activates canonical Smad signaling in fibroblasts, which upregulates LAMB3 expression via enhanced chromatin accessibility at the LAMB3 promoter; LAMB3 then initiates PI3K/AKT-dependent myofibroblast differentiation and renal fibrosis. Kidney-targeted knockdown of LAMB3 significantly ameliorates hypoxia-induced renal fibrosis in mice.","method":"ATAC-seq and RNA-seq (integrated), in vivo kidney-targeted LAMB3 knockdown, N-acetylcysteine (ROS scavenger) treatment, Western blot for Smad/AKT signaling, mouse hypoxic fibrosis model","journal":"Free radical biology & medicine","confidence":"High","confidence_rationale":"Tier 1 / Moderate — chromatin accessibility at LAMB3 promoter by ATAC-seq, in vivo loss-of-function, multiple orthogonal methods","pmids":["41412528"],"is_preprint":false},{"year":2023,"finding":"Ribosomal protein L35/uL29 (RpL35) ligands artesunate and atazanavir selectively increase production of full-length LAMB3 protein from PTC-containing mRNA via ribosome editing (targeted readthrough enhancement), producing up to 200% increase in full-length LAMB3 without affecting an unrelated PTC reporter.","method":"Dual luciferase reporter assays with LAMB3 PTC constructs vs. unrelated PTC reporter, drug treatment with artesunate and atazanavir","journal":"JID innovations","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assays demonstrating selective readthrough enhancement, selectivity confirmed by unrelated PTC control, single lab","pmids":["38282649"],"is_preprint":false},{"year":2023,"finding":"SOX10 deficiency in MAPK inhibitor-resistant melanoma cells drives LAMB3 upregulation through TGF-β signaling; elevated LAMB3 activates integrin α3/α6 signaling and a FAK/MMPs axis to promote migration and invasion; LAMB3 depletion inhibits metastatic potential of MAPKi-resistant cells in a mouse lung metastasis model.","method":"Transcriptome profiling, Western blot, siRNA knockdown, migration/invasion assays, in vivo lung metastasis mouse model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway dissection with knockdown and in vivo validation, single lab, multiple phenotypic readouts","pmids":["38102338"],"is_preprint":false},{"year":2026,"finding":"Tumor-derived LAMB3 promotes LRRC15+ fibroblast differentiation in PDAC through the ITGB1/FAK/MAPK signaling axis, leading to FOSL2-dependent transcriptional activation of LRRC15 in fibroblasts and suppression of T cell cytotoxicity; FAK inhibition partially reverses these effects and LAMB3 knockdown improves PD-1 blockade efficacy.","method":"Single-cell atlas, functional assays (overexpression/knockdown), orthotopic mouse models, FAK inhibition, ChIP/transcriptome analysis for FOSL2-LRRC15","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined signaling axis with pharmacological and genetic validation in vivo, single study","pmids":["42154006"],"is_preprint":false},{"year":2026,"finding":"LAMB3 overexpression in keratinocytes upregulates cytokeratin expression and accelerates wound healing in vivo; the LAMB3-ITGA6 axis coordinates epithelial adhesion (hemidesmosome-associated gene activation) and keratinization in gingival epithelial repair, with retinoic acid reciprocally regulating this axis.","method":"Single-cell RNA sequencing, LAMB3 knockdown and overexpression (lentivirus), phalloidin staining, in vivo mouse dorsal wound healing model, retinol/BMS493 treatment","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain/loss-of-function with defined in vivo wound healing phenotype, multiple orthogonal methods, single lab","pmids":["41960183"],"is_preprint":false}],"current_model":"LAMB3 encodes the β3 subunit of the heterotrimeric extracellular matrix protein laminin 332 (laminin 5); it is essential for laminin 332 trimer assembly with LAMA3 and LAMC2 subunits, and the assembled complex mediates epidermal-dermal adhesion by anchoring hemidesmosomes to the basement membrane. Loss-of-function mutations cause junctional epidermolysis bullosa and/or amelogenesis imperfecta. LAMB3 expression is transcriptionally regulated by TGF-β, by the BRD2/acetylated-ELK4 complex, by NF-κB (P65), by FOXQ1 (stabilized by PARP1), and epigenetically by promoter methylation/H3K4me3; its mRNA stability is enhanced by NAT10-mediated N4-acetylation. In cancer contexts, LAMB3 activates downstream PI3K/AKT, FAK/ERK, c-MET/AKT, RhoA/ROCK1/MYL9, WNT/β-catenin, and NRF2 signaling pathways to drive cell proliferation, invasion, metastasis, chemoresistance, and immune suppression; it physically interacts with LAMC2 and ITGB4/MDFI, and is targeted post-transcriptionally by miR-1298, miR-24-3p, and miR-133a-2 via its 3'UTR."},"narrative":{"mechanistic_narrative":"LAMB3 encodes the β3 chain of laminin 5/332, a basement-membrane component essential for dermal-epidermal adhesion and hemidesmosome assembly [PMID:7698759, PMID:9271670]. The β3 chain is a limiting subunit for laminin trimer assembly: it co-assembles with endogenous α3 and γ2 chains to deposit functional laminin in basement membranes, and restoring β3 alone is sufficient to rebuild laminin-332 and rescue adhesion phenotypes [PMID:16871230, PMID:29946029]. Loss-of-function mutations—nonsense, frameshift, splice-altering, and translation-reducing variants—abolish or attenuate laminin 332 and cause junctional epidermolysis bullosa, with milder hypomorphic alleles producing generalized atrophic benign EB [PMID:7698759, PMID:7706760, PMID:9501007, PMID:39357391]; β3 also functionally interacts with collagen XVII at the hemidesmosome anchoring complex, as shown by digenic JEB [PMID:10577906]. Within the epithelium, LAMB3 engages integrin partners (notably ITGB4/α6β4 and ITGA6) to coordinate hemidesmosome formation, keratinization, and wound repair [PMID:29946029, PMID:41960183]. In cancer and fibrotic contexts, LAMB3 is markedly upregulated and signals through integrin-coupled FAK/ERK and PI3K/AKT cascades to drive proliferation, invasion, metastasis, EMT, chemoresistance, and immune suppression [PMID:30850586, PMID:40540648, PMID:38102338, PMID:42154006]; it physically associates with LAMC2 and with ITGB4/MDFI to propagate these signals [PMID:36612197, PMID:38375821]. Its expression is controlled at multiple levels: transcriptionally by TGF-β/Smad with promoter chromatin opening [PMID:7635220, PMID:41412528], by NF-κB(P65) [PMID:37454278], by FOXQ1 [PMID:38297082], and by the BRD2/acetylated-ELK4 complex [PMID:32398865]; post-transcriptionally by NAT10-mediated ac4C mRNA stabilization [PMID:40540648] and by 3'UTR-targeting microRNAs including miR-1298 and miR-24-3p [PMID:27698189, PMID:32039003].","teleology":[{"year":1994,"claim":"Established LAMB3 as genetically essential for laminin 5 and skin adhesion by showing that nonsense mutations eliminate the protein and cause Herlitz JEB.","evidence":"Northern, RT-PCR, and sequencing of keratinocyte mRNA from H-JEB patients","pmids":["7698759"],"confidence":"High","gaps":["Did not define how β3 assembles with partner chains","No structural basis for adhesion loss"]},{"year":1995,"claim":"Defined the complete LAMB3 gene structure, providing the framework to map and interpret JEB mutations.","evidence":"Sequencing of overlapping phage clones and exon-intron boundaries","pmids":["7774918"],"confidence":"High","gaps":["Structural map alone does not assign functional domains to phenotypes"]},{"year":1995,"claim":"Linked specific short-arm domain VI mutations to milder GABEB and identified TGF-β as a non-coordinate inducer of LAMB3, opening regulatory study of the gene.","evidence":"Mutation analysis with EM/immunofluorescence; Northern hybridization after cytokine treatment of keratinocytes","pmids":["7706760","7635220"],"confidence":"Medium","gaps":["TGF-β transcriptional mechanism not resolved at this stage","Domain VI interaction with laminin 6 inferred, not biochemically shown"]},{"year":1996,"claim":"Showed recurrent CpG nonsense mutations dominate the H-JEB mutational spectrum, explaining allele recurrence across families.","evidence":"PCR, restriction digestion, and haplotype analysis across 14 families","pmids":["8824879"],"confidence":"High","gaps":["Does not address modifiers of phenotype severity"]},{"year":1998,"claim":"Demonstrated that hypomorphic LAMB3 alleles (splice-altering missense, mRNA-destabilizing frameshift) produce reduced but partly functional laminin and milder disease, establishing a dosage/quality genotype-phenotype axis.","evidence":"RT-PCR splice analysis, mRNA decay assays, sequencing, and genotype-phenotype correlation across multiple patients","pmids":["9501007","9767254","9690563"],"confidence":"High","gaps":["Quantitative threshold of functional laminin needed for adhesion undefined"]},{"year":1997,"claim":"Provided in vivo loss-of-function proof that LamB3 is required for hemidesmosome ultrastructure via a mouse IAP-insertion model.","evidence":"Linkage, Northern, immunohistochemistry, and EM of mutant mouse skin","pmids":["9271670"],"confidence":"High","gaps":["Did not test which partner chain assembly step is rate-limiting"]},{"year":1999,"claim":"Revealed functional interaction between LAMB3 and COL17A1 at the anchoring filament complex through digenic JEB.","evidence":"Mutation analysis, skin immunofluorescence, and hemidesmosome EM","pmids":["10577906"],"confidence":"High","gaps":["Direct physical β3-collagen XVII contact not demonstrated"]},{"year":2006,"claim":"Established β3 as the limiting subunit for laminin-5 trimer assembly by showing transgenic β3 co-assembles with endogenous α3/γ2 to rebuild basement-membrane laminin in deficient mice.","evidence":"Prenatal adenoviral/AAV LAMB3 delivery and immunohistochemical co-assembly assessment in H-JEB mice","pmids":["16871230"],"confidence":"Medium","gaps":["Single study with partial rescue","Stoichiometry of assembly not quantified"]},{"year":2011,"claim":"Identified epigenetic control of LAMB3 (promoter demethylation and H3K4me3) as a mechanism of its derepression in cancer.","evidence":"Methylation/expression profiling, H3K4me3 ChIP, and methylation-inhibitor treatment in gastric cancer cells","pmids":["21345334"],"confidence":"Medium","gaps":["Did not identify the transcription factors recruited to the active promoter"]},{"year":2013,"claim":"First established a functional pro-invasive/metastatic role for LAMB3 in cancer through loss-of-function.","evidence":"siRNA/shRNA knockdown with invasion assays and in vivo metastasis models in lung cancer","pmids":["23441154"],"confidence":"Medium","gaps":["Downstream signaling not yet mapped","Single lab"]},{"year":2016,"claim":"Placed LAMB3 downstream of oncogenic KRAS as a synthetic-lethal node, linking it to FAK and to microRNA control.","evidence":"miR-TRAP target capture, knockdown, and rescue co-expression with in vivo tumor growth","pmids":["27698189"],"confidence":"High","gaps":["Mechanism by which LAMB3 sustains KRAS-driven survival not fully defined"]},{"year":2018,"claim":"Demonstrated functional therapeutic restoration of laminin 332 by nonsense readthrough and by monoallelic gene correction, reconstituting adhesion and integrin polarization.","evidence":"Gentamicin readthrough across 8 PTC constructs and CRISPR/Cas9 HDR correction, with 3D skin equivalents and in vivo grafting","pmids":["29946029","30122422"],"confidence":"High","gaps":["Durability and efficiency of correction in patient tissue not established"]},{"year":2018,"claim":"Connected LAMB3 to specific oncogenic signaling axes (c-MET/AKT-driven EMT) in epithelial cancer.","evidence":"siRNA knockdown with invasion assays and Western blot for EMT markers, AKT, and c-MET in thyroid cancer","pmids":["29426928"],"confidence":"Medium","gaps":["Whether c-MET is a direct LAMB3 effector unresolved"]},{"year":2019,"claim":"Showed LAMB3 drives PDAC growth and metastasis via PI3K/AKT activation.","evidence":"siRNA knockdown, cell-cycle/apoptosis assays, xenograft and metastasis models, PI3K/AKT Western blot","pmids":["30850586"],"confidence":"Medium","gaps":["Receptor coupling LAMB3 to PI3K/AKT not identified here"]},{"year":2020,"claim":"Defined direct transcriptional and post-transcriptional regulators of LAMB3 in cancer and linked it to AKT-FOXO suppression.","evidence":"ChIP/luciferase/Co-IP for BRD2-ELK4 promoter binding with JQ1; dual-luciferase 3'UTR assay for miR-24-3p with rescue","pmids":["32398865","32039003"],"confidence":"High","gaps":["Relative contribution of each regulator in vivo not weighted"]},{"year":2022,"claim":"Confirmed direct LAMB3-LAMC2 physical interaction and identified additional upstream regulators (S100A10/JNK, PIGR-REST repression).","evidence":"Co-IP for LAMB3-LAMC2 and PIGR-REST, JNK inhibition, and rescue experiments in PDAC and CRC","pmids":["36612197","35992840"],"confidence":"Medium","gaps":["Single-lab Co-IP without reciprocal structural validation","Stoichiometry of LAMB3-LAMC2 in tumor context unknown"]},{"year":2023,"claim":"Established NF-κB(P65) as a direct LAMB3 transcriptional activator and connected LAMB3 to integrin α3β1/FAK signaling in inflammation.","evidence":"Dual-luciferase, ChIP-PCR, RNA-seq, and NF-κB inhibitor treatment in intestinal inflammation","pmids":["37454278"],"confidence":"High","gaps":["Whether the FAK output is identical across tissues not tested"]},{"year":2023,"claim":"Broadened LAMB3 signaling outputs to RhoA/ROCK1/MYL9 cytoskeletal remodeling, NRF2-dependent radioresistance, and integrin/FAK-driven metastasis in resistant melanoma.","evidence":"Gain/loss-of-function with pharmacological pathway manipulation in stromal cells, melanoma, and nasopharyngeal carcinoma, plus in vivo models","pmids":["37801199","36947579","38102338"],"confidence":"Medium","gaps":["These context-specific axes share an upstream integrin step that is not directly compared","Single lab per axis"]},{"year":2023,"claim":"Identified a translation-level disease mechanism (uORF-creating 5'UTR variant) and a ribosome-editing therapeutic strategy for PTC alleles.","evidence":"Luciferase translation assays, minigene splicing, structural analysis, and RpL35-ligand readthrough reporter assays","pmids":["39357391","38282649"],"confidence":"Medium","gaps":["Translational variant validated in reporter, not patient protein for the 5'UTR case","Ribosome-editing selectivity tested only in reporters"]},{"year":2024,"claim":"Resolved layered control and feedback of LAMB3 in cancer—NAT10 ac4C mRNA stabilization, FOXQ1/PARP1 transcriptional activation, YAP-TEAD4 feedback, MDFI/ITGB4 physical complex, and CRABP2 induction—each coupling LAMB3 to FAK/ERK, PI3K/AKT, MAPK, or WNT/β-catenin signaling and to immune suppression.","evidence":"acRIP, ChIP-seq/ChIP-PCR, Co-IP/MS, ubiquitination assays, RNA-seq, and in vivo tumor/immune models across PDAC, ovarian, CRC, and prostate cancer","pmids":["40540648","38297082","39016677","38375821","39038078"],"confidence":"High","gaps":["How a secreted matrix subunit triggers PD-L1/immune programs mechanistically incomplete","Most axes shown in one cancer type each"]},{"year":2024,"claim":"Extended LAMB3 immunosuppressive and stromal functions to LAMB3-CXCL2-driven CAF infiltration and to ITGA6-coordinated epithelial repair, identifying druggable upstream regulators (melatonin, retinoic acid).","evidence":"RNA-seq, knockdown/overexpression, immune profiling, and in vivo models in TNBC and gingival/wound repair","pmids":["39306019","41960183"],"confidence":"Medium","gaps":["Direct vs indirect LAMB3 control of CXCL2 not dissected","Single lab per system"]},{"year":2025,"claim":"Established LAMB3 as a profibrotic effector: TGF-β/Smad opens LAMB3 promoter chromatin to drive PI3K/AKT-dependent myofibroblast differentiation and renal fibrosis.","evidence":"Integrated ATAC-seq/RNA-seq, kidney-targeted LAMB3 knockdown, and Smad/AKT Western blot in a hypoxic fibrosis model","pmids":["41412528"],"confidence":"High","gaps":["Whether fibrosis depends on secreted laminin or intracellular signaling not separated"]},{"year":2026,"claim":"Mapped a tumor-stroma circuit in which secreted LAMB3 drives LRRC15+ fibroblast differentiation via ITGB1/FAK/MAPK and FOSL2, suppressing T cells and limiting PD-1 blockade.","evidence":"Single-cell atlas, gain/loss-of-function, FAK inhibition, ChIP for FOSL2-LRRC15, and orthotopic immune-competent models","pmids":["42154006"],"confidence":"Medium","gaps":["Receptor partner on fibroblasts not uniquely defined","Single study"]},{"year":null,"claim":"How a single matrix subunit switches between its structural adhesion role and a signaling/immunomodulatory role, and whether tumor effects require secreted laminin-332 assembly versus monomeric β3, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of β3 in tumor signaling complexes","Direct receptor(s) coupling LAMB3 to PI3K/AKT vs FAK/ERK not unified","Whether trimer assembly is required for oncogenic signaling untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,5,11,16]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[0,5,16]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,11,16]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[11,16]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[0,5,11,16]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[19,24,27,36]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[16,38]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,2,9,33]}],"complexes":["laminin 332 (laminin 5)","hemidesmosome anchoring filament complex"],"partners":["LAMC2","ITGB4","MDFI","ITGA6","COL17A1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13751","full_name":"Laminin subunit beta-3","aliases":["Epiligrin subunit beta","Kalinin B1 chain","Kalinin subunit beta","Laminin B1k chain","Laminin-5 subunit beta","Nicein subunit beta"],"length_aa":1172,"mass_kda":129.6,"function":"Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components","subcellular_location":"Secreted, extracellular space, extracellular matrix, basement membrane","url":"https://www.uniprot.org/uniprotkb/Q13751/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LAMB3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LAMB3","total_profiled":1310},"omim":[{"mim_id":"621324","title":"SECRETORY CALCIUM-BINDING PHOSPHOPROTEIN, PROLINE- AND GLUTAMINE-RICH, 1; SCPPPQ1","url":"https://www.omim.org/entry/621324"},{"mim_id":"620173","title":"TOOTH AGENESIS, SELECTIVE, 10; STHAG10","url":"https://www.omim.org/entry/620173"},{"mim_id":"619787","title":"EPIDERMOLYSIS BULLOSA, JUNCTIONAL 4, INTERMEDIATE; JEB4","url":"https://www.omim.org/entry/619787"},{"mim_id":"612920","title":"THROMBOSPONDIN-TYPE LAMININ G DOMAIN AND EAR REPEATS; TSPEAR","url":"https://www.omim.org/entry/612920"},{"mim_id":"600805","title":"LAMININ, ALPHA-3; LAMA3","url":"https://www.omim.org/entry/600805"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Vesicles","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"stomach 1","ntpm":69.1},{"tissue":"urinary bladder","ntpm":68.2}],"url":"https://www.proteinatlas.org/search/LAMB3"},"hgnc":{"alias_symbol":["nicein-125kDa","kalinin-140kDa","BM600-125kDa"],"prev_symbol":["LAMNB1"]},"alphafold":{"accession":"Q13751","domains":[{"cath_id":"2.60.120.260","chopping":"30-292","consensus_level":"medium","plddt":86.8797,"start":30,"end":292},{"cath_id":"2.170.300.10","chopping":"522-571","consensus_level":"medium","plddt":81.1142,"start":522,"end":571},{"cath_id":"-","chopping":"582-707","consensus_level":"medium","plddt":69.13,"start":582,"end":707}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13751","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13751-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13751-F1-predicted_aligned_error_v6.png","plddt_mean":78.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LAMB3","jax_strain_url":"https://www.jax.org/strain/search?query=LAMB3"},"sequence":{"accession":"Q13751","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13751.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13751/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13751"}},"corpus_meta":[{"pmid":"7698759","id":"PMC_7698759","title":"A homozygous nonsense mutation in the beta 3 chain gene of laminin 5 (LAMB3) in Herlitz junctional epidermolysis bullosa.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7698759","citation_count":196,"is_preprint":false},{"pmid":"30850586","id":"PMC_30850586","title":"LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30850586","citation_count":143,"is_preprint":false},{"pmid":"7706760","id":"PMC_7706760","title":"Altered laminin 5 expression due to mutations in the gene encoding the beta 3 chain (LAMB3) in generalized atrophic benign epidermolysis bullosa.","date":"1995","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/7706760","citation_count":113,"is_preprint":false},{"pmid":"8824879","id":"PMC_8824879","title":"Mutational hotspots in the LAMB3 gene in the lethal (Herlitz) type of junctional epidermolysis bullosa.","date":"1996","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8824879","citation_count":87,"is_preprint":false},{"pmid":"23441154","id":"PMC_23441154","title":"Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23441154","citation_count":78,"is_preprint":false},{"pmid":"9271670","id":"PMC_9271670","title":"IAP insertion in the murine LamB3 gene results in junctional epidermolysis bullosa.","date":"1997","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/9271670","citation_count":76,"is_preprint":false},{"pmid":"9326326","id":"PMC_9326326","title":"Maternal uniparental disomy of chromosome 1 with reduction to homozygosity of the LAMB3 locus in a patient with Herlitz junctional epidermolysis bullosa.","date":"1997","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9326326","citation_count":75,"is_preprint":false},{"pmid":"17476356","id":"PMC_17476356","title":"Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3.","date":"2007","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17476356","citation_count":72,"is_preprint":false},{"pmid":"10577906","id":"PMC_10577906","title":"Digenic junctional epidermolysis bullosa: mutations in COL17A1 and LAMB3 genes.","date":"1999","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10577906","citation_count":66,"is_preprint":false},{"pmid":"7706759","id":"PMC_7706759","title":"Identification of a homozygous one-basepair deletion in exon 14 of the LAMB3 gene in a patient with Herlitz junctional epidermolysis bullosa and prenatal diagnosis in a family at risk for recurrence.","date":"1995","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/7706759","citation_count":64,"is_preprint":false},{"pmid":"7550237","id":"PMC_7550237","title":"Detection of sequence variants in the gene encoding the beta 3 chain of laminin 5 (LAMB3).","date":"1995","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/7550237","citation_count":61,"is_preprint":false},{"pmid":"7635220","id":"PMC_7635220","title":"Differential cytokine modulation of the genes LAMA3, LAMB3, and LAMC2, encoding the constitutive polypeptides, alpha 3, beta 3, and gamma 2, of human laminin 5 in epidermal keratinocytes.","date":"1995","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/7635220","citation_count":58,"is_preprint":false},{"pmid":"23632796","id":"PMC_23632796","title":"Whole-exome sequencing, without prior linkage, identifies a mutation in LAMB3 as a cause of dominant hypoplastic amelogenesis imperfecta.","date":"2013","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/23632796","citation_count":57,"is_preprint":false},{"pmid":"32398865","id":"PMC_32398865","title":"LAMB3 promotes tumour progression through the AKT-FOXO3/4 axis and is transcriptionally regulated by the BRD2/acetylated ELK4 complex in colorectal cancer.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32398865","citation_count":56,"is_preprint":false},{"pmid":"21345334","id":"PMC_21345334","title":"Aberrant up-regulation of LAMB3 and LAMC2 by promoter demethylation in gastric cancer.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21345334","citation_count":56,"is_preprint":false},{"pmid":"20163849","id":"PMC_20163849","title":"Polymorphisms involved in the miR-218-LAMB3 pathway and susceptibility of cervical cancer, a case-control study in Chinese women.","date":"2010","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20163849","citation_count":55,"is_preprint":false},{"pmid":"29946029","id":"PMC_29946029","title":"Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa.","date":"2018","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29946029","citation_count":54,"is_preprint":false},{"pmid":"7774918","id":"PMC_7774918","title":"Cloning of the beta 3 chain gene (LAMB3) of human laminin 5, a candidate gene in junctional epidermolysis bullosa.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7774918","citation_count":54,"is_preprint":false},{"pmid":"30122422","id":"PMC_30122422","title":"CRISPR/Cas9-Mediated In Situ Correction of LAMB3 Gene in Keratinocytes Derived from a Junctional Epidermolysis Bullosa Patient.","date":"2018","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30122422","citation_count":52,"is_preprint":false},{"pmid":"23958762","id":"PMC_23958762","title":"LAMB3 mutations causing autosomal-dominant amelogenesis imperfecta.","date":"2013","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/23958762","citation_count":50,"is_preprint":false},{"pmid":"25867809","id":"PMC_25867809","title":"High Diagnostic Accuracy Based on CLDN10, HMGA2, and LAMB3 Transcripts in Papillary Thyroid Carcinoma.","date":"2015","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25867809","citation_count":49,"is_preprint":false},{"pmid":"27698189","id":"PMC_27698189","title":"miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27698189","citation_count":48,"is_preprint":false},{"pmid":"29426928","id":"PMC_29426928","title":"LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET/Akt signals.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29426928","citation_count":42,"is_preprint":false},{"pmid":"18331784","id":"PMC_18331784","title":"Clinical significance of LAMB3 and COL7A1 mRNA in esophageal squamous cell carcinoma.","date":"2008","source":"European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18331784","citation_count":41,"is_preprint":false},{"pmid":"11023379","id":"PMC_11023379","title":"Herlitz junctional epidermolysis bullosa: novel and recurrent mutations in the LAMB3 gene and the population carrier frequency.","date":"2000","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/11023379","citation_count":37,"is_preprint":false},{"pmid":"23778407","id":"PMC_23778407","title":"The role of micro RNAs let7c, 100 and 218 expression and their target RAS, C-MYC, BUB1, RB, SMARCA5, LAMB3 and Ki-67 in prostate cancer.","date":"2013","source":"Clinics (Sao Paulo, Brazil)","url":"https://pubmed.ncbi.nlm.nih.gov/23778407","citation_count":31,"is_preprint":false},{"pmid":"9242513","id":"PMC_9242513","title":"Predominance of the recurrent mutation R635X in the LAMB3 gene in European patients with Herlitz junctional epidermolysis bullosa has implications for mutation detection strategy.","date":"1997","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9242513","citation_count":31,"is_preprint":false},{"pmid":"29317832","id":"PMC_29317832","title":"Upregulated LAMB3 increases proliferation and metastasis in thyroid cancer.","date":"2017","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29317832","citation_count":28,"is_preprint":false},{"pmid":"30414703","id":"PMC_30414703","title":"LAMB3 is associated with disease progression and cisplatin cytotoxic sensitivity in head and neck squamous cell carcinoma.","date":"2018","source":"European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30414703","citation_count":28,"is_preprint":false},{"pmid":"9579554","id":"PMC_9579554","title":"Maternal uniparental meroisodisomy in the LAMB3 region of chromosome 1 results in lethal junctional epidermolysis bullosa.","date":"1998","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9579554","citation_count":28,"is_preprint":false},{"pmid":"32039003","id":"PMC_32039003","title":"MiR-24-3p Inhibits the Progression of Pancreatic Ductal Adenocarcinoma Through LAMB3 Downregulation.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32039003","citation_count":27,"is_preprint":false},{"pmid":"9501007","id":"PMC_9501007","title":"Compound heterozygosity for an out-of-frame deletion and a splice site mutation in the LAMB3 gene causes nonlethal junctional epidermolysis bullosa.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9501007","citation_count":26,"is_preprint":false},{"pmid":"8618058","id":"PMC_8618058","title":"Compound heterozygosity for nonsense ans missense mutations in the LAMB3 gene in nonlethal junctional epidermolysis bullosa.","date":"1996","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/8618058","citation_count":26,"is_preprint":false},{"pmid":"10964684","id":"PMC_10964684","title":"Differential expression of the LAMB3 and LAMC2 genes between small cell and non-small cell lung carcinomas.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10964684","citation_count":24,"is_preprint":false},{"pmid":"30046887","id":"PMC_30046887","title":"Identification of likely pathogenic and known variants in TSPEAR, LAMB3, BCOR, and WNT10A in four Turkish families with tooth agenesis.","date":"2018","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30046887","citation_count":24,"is_preprint":false},{"pmid":"32412777","id":"PMC_32412777","title":"LncRNA DDX11-AS1 Promotes Bladder Cancer Occurrence Via Protecting LAMB3 from Downregulation by Sponging miR-2355-5p.","date":"2020","source":"Cancer biotherapy & radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/32412777","citation_count":23,"is_preprint":false},{"pmid":"25769099","id":"PMC_25769099","title":"Novel ENAM and LAMB3 mutations in Chinese families with hypoplastic amelogenesis imperfecta.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25769099","citation_count":22,"is_preprint":false},{"pmid":"8618020","id":"PMC_8618020","title":"Compound heterozygosity for nonsense and missense mutations in the LAMB3 gene in nonlethal junctional epidermolysis bullosa.","date":"1996","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/8618020","citation_count":22,"is_preprint":false},{"pmid":"16871230","id":"PMC_16871230","title":"Evaluation of prenatal intra-amniotic LAMB3 gene delivery in a mouse model of Herlitz disease.","date":"2006","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16871230","citation_count":21,"is_preprint":false},{"pmid":"36612197","id":"PMC_36612197","title":"S100A10 Promotes Pancreatic Ductal Adenocarcinoma Cells Proliferation, Migration and Adhesion through JNK/LAMB3-LAMC2 Axis.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36612197","citation_count":20,"is_preprint":false},{"pmid":"29127567","id":"PMC_29127567","title":"The root of Actinidia chinensis inhibits hepatocellular carcinomas cells through LAMB3.","date":"2017","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/29127567","citation_count":20,"is_preprint":false},{"pmid":"38297082","id":"PMC_38297082","title":"PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/β-catenin signalling pathway.","date":"2024","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/38297082","citation_count":19,"is_preprint":false},{"pmid":"9690563","id":"PMC_9690563","title":"LAMB3 mutations in generalized atrophic benign epidermolysis bullosa: consequences at the mRNA and protein levels.","date":"1998","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9690563","citation_count":19,"is_preprint":false},{"pmid":"9767254","id":"PMC_9767254","title":"E210K mutation in the gene encoding the beta3 chain of laminin-5 (LAMB3) is predictive of a phenotype of generalized atrophic benign epidermolysis bullosa.","date":"1998","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9767254","citation_count":19,"is_preprint":false},{"pmid":"9457915","id":"PMC_9457915","title":"Novel mutations in the LAMB3 gene shared by two Japanese unrelated families with Herlitz junctional epidermolysis bullosa, and their application for prenatal testing.","date":"1998","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9457915","citation_count":19,"is_preprint":false},{"pmid":"15311214","id":"PMC_15311214","title":"Analysis of the LAMB3 gene in a junctional epidermolysis bullosa patient reveals exonic splicing and allele-specific nonsense-mediated mRNA decay.","date":"2004","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15311214","citation_count":19,"is_preprint":false},{"pmid":"27431458","id":"PMC_27431458","title":"Whole-Exome Sequencing Suggests LAMB3 as a Susceptibility Gene for Morbid Obesity.","date":"2016","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/27431458","citation_count":16,"is_preprint":false},{"pmid":"37086961","id":"PMC_37086961","title":"Tumor-derived extracellular vesicles delivering TNF-α promotes colorectal cancer metastasis via the NF-kB/LAMB3/AKT axis by targeting SNAP23.","date":"2023","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/37086961","citation_count":13,"is_preprint":false},{"pmid":"27062385","id":"PMC_27062385","title":"A unique LAMB3 splice-site mutation with founder effect from the Balkans causes lethal epidermolysis bullosa in several European countries.","date":"2016","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/27062385","citation_count":13,"is_preprint":false},{"pmid":"27220909","id":"PMC_27220909","title":"A novel de novo mutation in LAMB3 causes localized hypoplastic enamel in the molar region.","date":"2016","source":"European journal of oral sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27220909","citation_count":13,"is_preprint":false},{"pmid":"39214450","id":"PMC_39214450","title":"The LAMB3-EGFR signaling pathway mediates synergistic Anti-Cancer effects of berberine and emodin in Pancreatic cancer.","date":"2024","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39214450","citation_count":12,"is_preprint":false},{"pmid":"39306019","id":"PMC_39306019","title":"Melatonin increases Olaparib sensitivity and suppresses cancer-associated fibroblast infiltration via suppressing the LAMB3-CXCL2 axis in TNBC.","date":"2024","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/39306019","citation_count":12,"is_preprint":false},{"pmid":"35992840","id":"PMC_35992840","title":"Polymeric immunoglobulin receptor suppresses colorectal cancer through the AKT-FOXO3/4 axis by downregulating LAMB3 expression.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35992840","citation_count":12,"is_preprint":false},{"pmid":"40540648","id":"PMC_40540648","title":"NAT10 regulates tumor progression and immune microenvironment in pancreatic ductal adenocarcinoma via the N4-acetylated LAMB3-mediated FAK/ERK pathway.","date":"2025","source":"Cancer communications (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/40540648","citation_count":11,"is_preprint":false},{"pmid":"37577750","id":"PMC_37577750","title":"Multi-omics analysis of LAMB3 as a potential immunological and biomarker in pan-cancer.","date":"2023","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/37577750","citation_count":11,"is_preprint":false},{"pmid":"36305754","id":"PMC_36305754","title":"hsa-mir-133a-2 promotes the proliferation and invasion of cervical cancer cells by targeting the LAMB3-mediated PI3K/ATK pathway.","date":"2022","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36305754","citation_count":10,"is_preprint":false},{"pmid":"38375821","id":"PMC_38375821","title":"MDFI promotes the proliferation and tolerance to chemotherapy of colorectal cancer cells by binding ITGB4/LAMB3 to activate the AKT signaling pathway.","date":"2024","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38375821","citation_count":10,"is_preprint":false},{"pmid":"37454278","id":"PMC_37454278","title":"LAMB3 Promotes Intestinal Inflammation Through SERPINA3 and Is Directly Transcriptionally Regulated by P65 in Inflammatory Bowel Disease.","date":"2024","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/37454278","citation_count":9,"is_preprint":false},{"pmid":"16372803","id":"PMC_16372803","title":"[Dental alterations in junctional epidermolysis bullosa--report of a patient with a mutation in the LAMB3-gene].","date":"2005","source":"Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG","url":"https://pubmed.ncbi.nlm.nih.gov/16372803","citation_count":9,"is_preprint":false},{"pmid":"39111076","id":"PMC_39111076","title":"LAMB3: Central role and clinical significance in neoplastic and non-neoplastic diseases.","date":"2024","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/39111076","citation_count":8,"is_preprint":false},{"pmid":"39038078","id":"PMC_39038078","title":"CRABP2 promotes cell migration and invasion by activating PI3K/AKT and MAPK signalling pathways via upregulating LAMB3 in prostate cancer.","date":"2024","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39038078","citation_count":8,"is_preprint":false},{"pmid":"32906717","id":"PMC_32906717","title":"LAMB3 Missense Variant in Australian Shepherd Dogs with Junctional Epidermolysis Bullosa.","date":"2020","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/32906717","citation_count":8,"is_preprint":false},{"pmid":"36947579","id":"PMC_36947579","title":"Knockdown of LAMB3 suppressed radioresistance in nasopharyngeal carcinoma via deactivating NRF2 signaling pathway.","date":"2023","source":"Journal of radiation research","url":"https://pubmed.ncbi.nlm.nih.gov/36947579","citation_count":7,"is_preprint":false},{"pmid":"9583749","id":"PMC_9583749","title":"Molecular basis of non-lethal junctional epidermolysis bullosa: identification of a 38 basepair insertion and a splice site mutation in exon 14 of the LAMB3 gene.","date":"1998","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9583749","citation_count":7,"is_preprint":false},{"pmid":"37801199","id":"PMC_37801199","title":"LAMB3 Promotes Myofibrogenesis and Cytoskeletal Reorganization in Endometrial Stromal Cells via the RhoA/ROCK1/MYL9 Pathway.","date":"2023","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/37801199","citation_count":6,"is_preprint":false},{"pmid":"10660342","id":"PMC_10660342","title":"Laminin 5 genes and Herlitz junctional epidermolysis bullosa: novel mutations and polymorphisms in the LAMB3 and LAMC2 genes. Mutations in brief no. 190. Online.","date":"1998","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10660342","citation_count":6,"is_preprint":false},{"pmid":"38473784","id":"PMC_38473784","title":"Downregulation of LAMB3 Altered the Carcinogenic Properties of Human Papillomavirus 16-Positive Cervical Cancer Cells.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38473784","citation_count":5,"is_preprint":false},{"pmid":"36246619","id":"PMC_36246619","title":"Identification of a novel homozygous LAMB3 mutation in a Chinese male with junctional epidermolysis bullosa and severe urethra stenosis: A case report.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36246619","citation_count":4,"is_preprint":false},{"pmid":"10951252","id":"PMC_10951252","title":"Compound heterozygosity for a point mutation and a deletion located at splice acceptor sites in the LAMB3 gene leads to generalized atrophic benign epidermolysis bullosa.","date":"2000","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/10951252","citation_count":4,"is_preprint":false},{"pmid":"23278291","id":"PMC_23278291","title":"Herlitz junctional epidermolysis bullosa with a novel mutation in LAMB3.","date":"2012","source":"Pediatric dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/23278291","citation_count":4,"is_preprint":false},{"pmid":"38200141","id":"PMC_38200141","title":"Single-cell sequencing reveals increased LAMB3-positive basal keratinocytes and ZNF90-positive fibroblasts in autologous cultured epithelium.","date":"2024","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/38200141","citation_count":3,"is_preprint":false},{"pmid":"36415640","id":"PMC_36415640","title":"Decreased Expression of LAMB3 Is Associated with Esophageal Cancer Stem Cell Formation.","date":"2021","source":"Advanced pharmaceutical bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/36415640","citation_count":3,"is_preprint":false},{"pmid":"38282649","id":"PMC_38282649","title":"En Route to Targeted Ribosome Editing to Replenish Skin Anchor Protein LAMB3 in Junctional Epidermolysis Bullosa.","date":"2023","source":"JID innovations : skin science from molecules to population health","url":"https://pubmed.ncbi.nlm.nih.gov/38282649","citation_count":3,"is_preprint":false},{"pmid":"30544381","id":"PMC_30544381","title":"Targeted next-generation sequencing identifies a novel mutation of LAMB3 in a Chinese neonatal patient presented with junctional epidermolysis bullosa.","date":"2018","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30544381","citation_count":3,"is_preprint":false},{"pmid":"37888105","id":"PMC_37888105","title":"Recessive COL17A1 Mutations and a Dominant LAMB3 Mutation Cause Hypoplastic Amelogenesis Imperfecta.","date":"2023","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37888105","citation_count":2,"is_preprint":false},{"pmid":"38102338","id":"PMC_38102338","title":"SOX10 deficiency-mediated LAMB3 upregulation determines the invasiveness of MAPKi-resistant melanoma.","date":"2023","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/38102338","citation_count":2,"is_preprint":false},{"pmid":"36468719","id":"PMC_36468719","title":"A novel splice-site variant of the LAMB3 gene is associated with junctional epidermolysis bullosa.","date":"2022","source":"European journal of dermatology : EJD","url":"https://pubmed.ncbi.nlm.nih.gov/36468719","citation_count":2,"is_preprint":false},{"pmid":"36072792","id":"PMC_36072792","title":"Corrigendum: Polymeric immunoglobulin receptor suppresses colorectal cancer through the AKT-FOXO3/4 axis by downregulating LAMB3 expression.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36072792","citation_count":2,"is_preprint":false},{"pmid":"36299258","id":"PMC_36299258","title":"Rare compound heterozygous variants of LAMB3 and histological features of enamel and oral mucosa.","date":"2022","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/36299258","citation_count":1,"is_preprint":false},{"pmid":"36267689","id":"PMC_36267689","title":"Modified Non-Cultured Cell Spray Induced Epithelization in LAMB3 Mutation Epidermolysis Bullosa.","date":"2022","source":"Clinical, cosmetic and investigational dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/36267689","citation_count":1,"is_preprint":false},{"pmid":"40100311","id":"PMC_40100311","title":"A homozygous LAMB3 frameshift variant in junctional epidermolysis bullosa-affected Bleu du Maine sheep.","date":"2025","source":"Journal of applied genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40100311","citation_count":1,"is_preprint":false},{"pmid":"9209887","id":"PMC_9209887","title":"Identification of the LAMB3 hotspot mutation R635X in a Hungarian case of Herlitz junctional epidermolysis bullosa.","date":"1997","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/9209887","citation_count":1,"is_preprint":false},{"pmid":"41412528","id":"PMC_41412528","title":"TGF-β/LAMB3 axis drives ROS-dependent renal fibrosis under hypoxic conditions.","date":"2025","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41412528","citation_count":0,"is_preprint":false},{"pmid":"42154006","id":"PMC_42154006","title":"Tumor-Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development.","date":"2026","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/42154006","citation_count":0,"is_preprint":false},{"pmid":"41139196","id":"PMC_41139196","title":"Full-length transcriptome analysis of papillary thyroid carcinoma reveals correlation between LAMB3 expression and clinical features.","date":"2025","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/41139196","citation_count":0,"is_preprint":false},{"pmid":"39016677","id":"PMC_39016677","title":"YAP-LAMB3 axis dictates cellular resistance of pancreatic ductal adenocarcinoma cells to gemcitabine.","date":"2024","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/39016677","citation_count":0,"is_preprint":false},{"pmid":"42002036","id":"PMC_42002036","title":"Single-cell Analysis Reveals a LAMB3-dependent Immunosuppressive Environment in Gallbladder Neck/Cystic Duct Carcinoma.","date":"2026","source":"JHEP reports : innovation in hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/42002036","citation_count":0,"is_preprint":false},{"pmid":"41960183","id":"PMC_41960183","title":"The LAMB3-ITGA6 axis orchestrates epithelial repair in periodontitis via hemidesmosomal regulation and keratinization modulation.","date":"2026","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/41960183","citation_count":0,"is_preprint":false},{"pmid":"41492568","id":"PMC_41492568","title":"Ophthalmic phenotype associated with a novel mutation in LAMB3 gene linked to uncommon Intermediate Junctional Epidermolysis Bullosa.","date":"2025","source":"American journal of ophthalmology case reports","url":"https://pubmed.ncbi.nlm.nih.gov/41492568","citation_count":0,"is_preprint":false},{"pmid":"39357391","id":"PMC_39357391","title":"An intronic variant in LAMB3 contributes to junctional epidermolysis bullosa and enamel hypoplasia via translational attenuation.","date":"2024","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/39357391","citation_count":0,"is_preprint":false},{"pmid":"41728083","id":"PMC_41728083","title":"A Case of Neonatal Junctional Epidermolysis Bullosa With a LAMB3 Mutation: Diagnostic Journey and Interdisciplinary Management.","date":"2026","source":"Case reports in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/41728083","citation_count":0,"is_preprint":false},{"pmid":"35178765","id":"PMC_35178765","title":"Junctional epidermolysis bullosa with extensive lung involvement in three patients with a LAMB3 Mutation.","date":"2022","source":"Pediatric dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/35178765","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46013,"output_tokens":9494,"usd":0.140225,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19999,"output_tokens":6182,"usd":0.127273,"stage2_stop_reason":"end_turn"},"total_usd":0.267498,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"Homozygous nonsense mutations (premature termination codons) in LAMB3, encoding the β3 chain of laminin 5, cause complete absence of laminin 5 protein and result in Herlitz junctional epidermolysis bullosa (H-JEB), establishing LAMB3 as essential for laminin 5 assembly and dermal-epidermal adhesion.\",\n      \"method\": \"Northern hybridization, RT-PCR, direct nucleotide sequencing of keratinocyte mRNA, genomic DNA verification\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct mutation identification with mRNA and protein consequence, replicated across many subsequent studies\",\n      \"pmids\": [\"7698759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The human LAMB3 gene consists of 23 exons spanning ~29 kb, encoding 1172 amino acids; its exon-intron organization is more compact than LAMB1, and this structure was used to establish the molecular basis of JEB mutations.\",\n      \"method\": \"Characterization of overlapping lambda phage DNA clones, sequencing of exon-intron boundaries, comparison with LAMB1 gene structure\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — complete gene structure determined by direct sequencing, foundational structural characterization\",\n      \"pmids\": [\"7774918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Mutations in LAMB3 exons 3 and 7 (encoding part of domain VI of the β3 chain short arm) cause generalized atrophic benign epidermolysis bullosa; the domain VI globular domain is postulated to mediate interaction of laminin 5 with laminin 6 (K-laminin), and its disruption reduces epidermal-dermal adhesion.\",\n      \"method\": \"PCR amplification of genomic DNA, heteroduplex analysis, nucleotide sequencing, immunofluorescence and immunoelectron microscopy, transmission electron microscopy\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mutation identified with protein-level consequence validated by immunofluorescence and electron microscopy\",\n      \"pmids\": [\"7706760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"TGF-β upregulates LAMB3 gene expression in human epidermal keratinocytes (as well as HaCaT and Balb/K cells), whereas TNF-α alone does not alter LAMB3 expression; the three laminin 5 subunit genes (LAMA3, LAMB3, LAMC2) are not coordinately regulated by these cytokines.\",\n      \"method\": \"Northern hybridization with specific cDNA probes, cytokine treatment of cultured keratinocytes\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Northern hybridization in multiple cell lines, single lab, consistent across cell types\",\n      \"pmids\": [\"7635220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Two recurrent nonsense mutations in LAMB3, R42X and R635X (at CpG dinucleotides), account for over 50% of mutant LAMB3 alleles in H-JEB families; haplotype analysis demonstrated R635X arose on different genetic backgrounds, confirming CpG hypermutability as a mechanism.\",\n      \"method\": \"PCR, restriction enzyme digestion, haplotype analysis with intragenic polymorphisms, pedigree analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated across 14 families, haplotype analysis confirming independent mutational events\",\n      \"pmids\": [\"8824879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Insertion of an intracisternal-A particle (IAP) into the LamB3 coding sequence in mice abolishes LamB3 mRNA and laminin-5 protein expression, causing sub-epithelial blisters and abnormal hemidesmosomes lacking sub-basal dense plates, establishing a functional role for laminin-5/LAMB3 in hemidesmosome formation.\",\n      \"method\": \"Linkage analysis, Northern blot, immunohistochemistry, DNA sequence analysis of IAP insertion site, transmission electron microscopy\",\n      \"journal\": \"Mammalian genome\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo loss-of-function model with defined ultrastructural phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"9271670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"A missense mutation E210K (628G→A) at the last nucleotide of LAMB3 exon 7 causes both an amino acid substitution and aberrant splicing, generating multiple aberrant mRNA species and reduced expression of laminin 5 with altered biological activity, resulting in a mild (non-lethal) JEB phenotype.\",\n      \"method\": \"RT-PCR analysis of aberrant splice variants, sequencing, mRNA decay analysis, immunofluorescence\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mutation characterized at both mRNA and protein levels with multiple orthogonal methods\",\n      \"pmids\": [\"9501007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The LAMB3 missense mutation E210K in compound heterozygosity with a nonsense mutation is predictive of generalized atrophic benign EB phenotype; the combination of a null allele and E210K allows reduced expression of a partly functional laminin 5 protein.\",\n      \"method\": \"PCR, heteroduplex analysis, direct sequencing, genotype-phenotype correlation across three patients\",\n      \"journal\": \"The British journal of dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genotype-phenotype correlation confirmed in three independent patients, single method (sequencing)\",\n      \"pmids\": [\"9767254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"A LAMB3 frameshift mutation (1367delAC) causes accelerated mRNA decay, rendering the transcript undetectable by RT-PCR; a missense mutation (C293S) in the other allele results in reduced laminin 5 expression in generalized atrophic benign EB.\",\n      \"method\": \"Heteroduplex scanning, direct automated sequencing, RT-PCR for mRNA stability assessment\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mRNA consequences of specific mutations directly characterized, two orthogonal methods\",\n      \"pmids\": [\"9690563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Digenic JEB can result from mutations in both COL17A1 and LAMB3: compound heterozygous COL17A1 null mutations combined with one LAMB3 null allele (R635X heterozygosity) causes absence of collagen XVII and attenuated laminin 5 expression, rudimentary hemidesmosome structure, and severe blistering—demonstrating functional interaction between these two hemidesmosome-anchoring filament complex proteins.\",\n      \"method\": \"Mutation analysis by sequencing, immunofluorescence of skin, electron microscopy of hemidesmosome structure\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — epistatic interaction between two genes confirmed by protein expression and ultrastructural analysis\",\n      \"pmids\": [\"10577906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"A synonymous LAMB3 variant (3009C→T in exon 20) creates a novel exonic splice site that is preferentially used by the spliceosome over the wild-type splice site despite having a lower splice score (68.6 vs. 92.2); the resulting aberrant mRNA leads to a stop codon in exon 21 and undergoes allele-specific nonsense-mediated mRNA decay.\",\n      \"method\": \"DNA sequencing, RT-PCR analysis of splice variants, computational splice-site scoring, immunohistochemistry/immunoelectron microscopy\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — splicing mechanism directly characterized at mRNA level with computational validation and functional consequence\",\n      \"pmids\": [\"15311214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Prenatal delivery of LAMB3 cDNA via adenoviral and AAV vectors to laminin-5 β3-deficient mice showed that the transgenic β3 chain assembles with endogenous partner chains (α3 and γ2) to produce laminin-5, which deposits in basement membranes of skin and mucosae, reducing tissue separation—demonstrating that LAMB3/β3 chain is a limiting subunit for laminin-5 trimer assembly.\",\n      \"method\": \"In vivo prenatal gene delivery, immunohistochemistry for laminin-5, co-assembly assessment in basement membranes of H-JEB mice\",\n      \"journal\": \"Gene therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo reconstitution of trimer assembly, single study with partial therapeutic rescue\",\n      \"pmids\": [\"16871230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Multiple distinct second-site mutations in LAMB3 can correct the germline E210K mutation in vivo (revertant mosaicism), restoring laminin-332 expression in naturally corrected keratinocytes; different correcting mechanisms (splice site alterations, missense changes) all restored normal laminin-332, confirming the necessity of intact LAMB3 for laminin-332 assembly.\",\n      \"method\": \"DNA analysis of revertant keratinocytes from multiple biopsy specimens, immunofluorescence for laminin-332, sequencing of second-site mutations\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple independent revertant events confirmed by sequencing and protein expression, natural in vivo experiment\",\n      \"pmids\": [\"17476356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LAMB3 expression in gastric cancer is regulated epigenetically: promoter demethylation (DNA hypomethylation) is associated with LAMB3 upregulation, and the active histone mark H3K4me3 is associated with its expression; treatment with a methylation inhibitor induces LAMB3 expression in silenced cell lines.\",\n      \"method\": \"Combined DNA methylation and gene expression analysis, chromatin immunoprecipitation (ChIP) assay for H3K4me3, methylation inhibitor treatment\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus methylation inhibitor experiments, single lab, two orthogonal methods\",\n      \"pmids\": [\"21345334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Knockdown of LAMB3 suppresses invasion and metastasis of lung cancer cells in vitro and in vivo, establishing a functional role for LAMB3 in cancer cell invasive behavior.\",\n      \"method\": \"siRNA and lentiviral shRNA knockdown, invasion/migration assays in vitro, in vivo tumor metastasis models\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined cellular and in vivo phenotypes, single lab\",\n      \"pmids\": [\"23441154\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"miR-1298 inhibits KRAS-driven cancer cell growth by directly targeting LAMB3 (and FAK); silencing LAMB3 alone recapitulates the synthetic lethal effect of miR-1298, while co-expression of LAMB3 and FAK rescues miR-1298-induced cell death, placing LAMB3 downstream of mutant KRAS signaling.\",\n      \"method\": \"miR-TRAP affinity purification to identify LAMB3 as miR-1298 target, siRNA knockdown, rescue co-expression experiments, in vivo tumor growth assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — miR-TRAP affinity purification to identify target, validated by knockdown and rescue experiments in vitro and in vivo\",\n      \"pmids\": [\"27698189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Gentamicin induces readthrough of LAMB3 premature termination codons (including R635X and C290X) in H-JEB keratinocytes, producing full-length laminin β3 in a dose-dependent manner; this restored laminin 332 assembly, secretion, deposition at the dermal-epidermal junction, proper α6β4 integrin polarization, and corrected abnormal cell morphology, poor growth, poor adhesion, and hypermotility.\",\n      \"method\": \"Transfection of expression vectors with 8 different LAMB3 nonsense mutations, lentiviral stable transduction, gentamicin treatment, immunoblot, immunofluorescence, 3D skin equivalent model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — functional reconstitution of full laminin 332 assembly with multiple orthogonal methods and 8 different mutations tested\",\n      \"pmids\": [\"29946029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LAMB3 suppression in papillary thyroid cancer reduces cell migration and invasion via downregulation of EMT-associated proteins (N-cadherin, vimentin, slug) and inhibition of MMP9; LAMB3 inhibition also significantly decreases AKT phosphorylation and inhibits c-MET transcription, indicating LAMB3 promotes invasion via the HGF/c-MET/AKT axis.\",\n      \"method\": \"siRNA knockdown, migration/invasion assays, Western blot for EMT markers, AKT phosphorylation, and c-MET\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with multiple downstream signaling readouts, single lab\",\n      \"pmids\": [\"29426928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CRISPR/Cas9-mediated HDR using an adenovector (Cas9/gRNA targeting intron 2) and an integration-defective lentiviral vector (promoterless LAMB3 cDNA with splice acceptor) restores monoallelic LAMB3 expression in JEB keratinocytes; monoallelic correction was sufficient to restore adhesion, colony formation, and normal dermal-epidermal junction in skin equivalents transplanted onto immunodeficient mice.\",\n      \"method\": \"CRISPR/Cas9 HDR gene correction, in vitro adhesion and colony formation assays, in vivo skin equivalent grafting\",\n      \"journal\": \"Molecular therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution of function by precise gene correction with in vitro and in vivo validation\",\n      \"pmids\": [\"30122422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"LAMB3 inhibition in pancreatic ductal adenocarcinoma cells abrogates PI3K/AKT pathway activation, causing cell cycle arrest and apoptosis, and reduces proliferation, invasion, migration, tumor growth, and liver metastasis in vivo.\",\n      \"method\": \"siRNA knockdown, cell cycle analysis, apoptosis assays, invasion/migration assays in vitro, xenograft and liver metastasis models in vivo, Western blot for PI3K/AKT pathway\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with in vitro and in vivo phenotypes plus signaling pathway readout, single lab\",\n      \"pmids\": [\"30850586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"LAMB3 transcription in colorectal cancer is directly regulated by the BRD2/acetylated-ELK4 complex: ELK4 (acetylated at K125) cooperates with BRD2 to bind ETS motifs in the LAMB3 promoter; BET inhibitor JQ1 disrupts the ELK4-BRD2 interaction and reduces BRD2 binding to the LAMB3 promoter, downregulating LAMB3. Downstream, LAMB3 activates AKT to inhibit FOXO3/4 tumor-suppressive function.\",\n      \"method\": \"ChIP assay, luciferase reporter assays for promoter binding, Co-IP for ELK4-BRD2 interaction, JQ1/U0126 inhibitor treatment, Western blot, in vitro and in vivo tumor models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct promoter binding confirmed by ChIP, protein interaction by Co-IP, functional readout with inhibitors, multiple orthogonal methods in single study\",\n      \"pmids\": [\"32398865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-24-3p directly targets the LAMB3 3'UTR to suppress LAMB3 expression in pancreatic ductal adenocarcinoma cells; overexpression of miR-24-3p inhibits PDAC proliferation, cell cycle progression, and invasion by suppressing LAMB3, and this was confirmed in a xenograft model.\",\n      \"method\": \"Dual-luciferase reporter assay targeting LAMB3 3'UTR, FISH for subcellular localization of miR-24-3p and LAMB3 mRNA, rescue assays, subcutaneous xenograft\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct 3'UTR targeting confirmed by luciferase assay plus rescue experiments, single lab\",\n      \"pmids\": [\"32039003\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"S100A10 activates LAMB3 expression through the JNK pathway in pancreatic ductal adenocarcinoma; LAMB3 was shown to physically interact with LAMC2, and LAMB3 mediates the effects of S100A10 on cell proliferation, migration, and adhesion.\",\n      \"method\": \"RNA-sequencing, Western blotting, co-immunoprecipitation for LAMB3-LAMC2 interaction, JNK pathway inhibition, knockdown/overexpression rescue experiments, orthotopic tumor model\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for LAMB3-LAMC2 interaction plus signaling pathway rescue experiments, single lab\",\n      \"pmids\": [\"36612197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PIGR physically associates with the transcriptional repressor REST and blocks REST-mediated transcription of LAMB3 in colorectal cancer; PIGR overexpression downregulates LAMB3, suppressing the AKT-FOXO3/4 axis and inhibiting CRC cell malignant phenotypes.\",\n      \"method\": \"Co-immunoprecipitation of PIGR-REST complex, Western blot, in vitro functional assays, in vivo xenograft\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for PIGR-REST interaction, LAMB3 as downstream target, functional readout, single lab\",\n      \"pmids\": [\"35992840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LAMB3 promotes intestinal inflammation through upregulation of SERPINA3 via the integrin α3β1/FAK pathway; NF-κB (P65) directly transcriptionally activates LAMB3 under TNF-α stimulation, as demonstrated by dual-luciferase assays and ChIP-PCR.\",\n      \"method\": \"Dual-luciferase assay, ChIP-PCR, RNA-sequencing, qRT-PCR, Western blotting, NF-κB inhibitor treatment\",\n      \"journal\": \"Inflammatory bowel diseases\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct transcriptional regulation confirmed by ChIP-PCR and luciferase assays, downstream pathway by RNA-seq and rescue, multiple orthogonal methods\",\n      \"pmids\": [\"37454278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LAMB3 knockdown in nasopharyngeal carcinoma cells promotes apoptosis and reduces radioresistance by enhancing FOXO3 expression and thereby deactivating the NRF2 signaling pathway, leading to increased ROS accumulation after X-ray treatment.\",\n      \"method\": \"shRNA knockdown, ROS measurement, Western blot for NRF2/FOXO3 pathway, rescue experiments with NRF2 suppression, in vivo xenograft irradiation model\",\n      \"journal\": \"Journal of radiation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with downstream pathway rescue, confirmed in vivo, single lab\",\n      \"pmids\": [\"36947579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"LAMB3 promotes myofibrogenesis and cytoskeletal reorganization in endometrial stromal cells via the RhoA/ROCK1/MYL9 pathway; LAMB3 overexpression promotes TGF-β-induced myofibroblast phenotype conversion and actin cytoskeleton remodeling, while LAMB3 silencing reverses these effects, and both are abrogated by the ROCK inhibitor Y-27632 or the RhoA activator LPA.\",\n      \"method\": \"LAMB3 overexpression and knockdown in primary endometrial stromal cells, PCR, Western blot, phalloidin staining for actin cytoskeleton, pharmacological inhibition/activation of RhoA/ROCK pathway\",\n      \"journal\": \"Cell biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with pharmacological pathway manipulation, two orthogonal methods, single lab\",\n      \"pmids\": [\"37801199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NAT10 enhances LAMB3 mRNA stability via N4-acetylcytidine (ac4C) modification of LAMB3 mRNA; stabilized LAMB3 then activates the FAK/ERK pathway to promote PDAC tumor progression and upregulate PD-L1 expression, reducing CD8+ T cell cytotoxicity.\",\n      \"method\": \"Acetylated RNA immunoprecipitation (acRIP), qPCR, RNA immunoprecipitation, Western blotting, single-cell RNA sequencing, multiplexed immunofluorescence, flow cytometry, in vivo mouse models\",\n      \"journal\": \"Cancer communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct mRNA modification identified by acRIP, downstream FAK/ERK signaling confirmed by Western blot, multiple orthogonal methods\",\n      \"pmids\": [\"40540648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"FOXQ1, stabilized by PARP1 (via inhibition of E3 ubiquitin ligase CHIP-mediated degradation), directly binds the LAMB3 promoter region to activate LAMB3 transcription, which in turn activates the WNT/β-catenin signaling pathway to promote ovarian cancer progression.\",\n      \"method\": \"Co-IP, mass spectrometry, ubiquitination assays, ChIP-seq, ChIP-PCR, luciferase assays, RNA-seq, GSEA, Western blot, in vivo animal models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct promoter binding by ChIP-seq/ChIP-PCR, PARP1-FOXQ1 interaction by Co-IP and MS, ubiquitination mechanism characterized, multiple orthogonal methods\",\n      \"pmids\": [\"38297082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"MDFI directly interacts with LAMB3 (and ITGB4) in colorectal cancer cells, as confirmed by co-immunoprecipitation; MDFI upregulates the AKT pathway via its binding to LAMB3/ITGB4, enhancing CRC cell proliferation and reducing sensitivity to oxaliplatin and fluorouracil.\",\n      \"method\": \"Single-cell RNA sequencing, co-immunoprecipitation for MDFI-LAMB3/ITGB4 interaction, knockdown and lentiviral overexpression, Western blot, colony formation and CCK-8 assays\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP confirming direct LAMB3-MDFI interaction, functional pathway activation, single lab\",\n      \"pmids\": [\"38375821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LAMB3 mediates gemcitabine resistance in PDAC through a YAP-LAMB3 feedback axis: YAP activates LAMB3 transcription via TEAD4, and LAMB3 in turn amplifies YAP signaling; this axis drives epithelial-mesenchymal transition and Gem resistance.\",\n      \"method\": \"Knockdown and overexpression experiments, in vitro drug sensitivity assays, Western blot for YAP/TEAD4/EMT markers, in vivo xenograft model\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain/loss-of-function establishing feedback loop, drug resistance phenotype validated in vivo, single lab\",\n      \"pmids\": [\"39016677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"LAMB3 knockdown decreases CXCL2 expression, reduces cancer-associated fibroblast (CAF) infiltration, and increases olaparib sensitivity in triple-negative breast cancer; melatonin downregulates LAMB3, and the LAMB3-CXCL2 axis was found to collaboratively promote CAF infiltration and immunosuppression.\",\n      \"method\": \"RNA-sequencing, genetic ablation (LAMB3 knockdown), Western blot, in vivo tumor models with combination treatment, immune cell profiling\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq plus loss-of-function with downstream CXCL2 and immune phenotype, in vivo validation, single lab\",\n      \"pmids\": [\"39306019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CRABP2 upregulates LAMB3 mRNA and protein expression (shown by RNA-seq and Western blot), and LAMB3 in turn activates the PI3K/AKT and MAPK signaling pathways to promote cell migration and invasion in prostate cancer.\",\n      \"method\": \"RNA-seq after CRABP2 overexpression, Western blot for LAMB3 and downstream pathway proteins, migration/invasion assays, in vivo tumor model\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq identification with Western blot validation, downstream signaling confirmed, single lab\",\n      \"pmids\": [\"39038078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"An intronic LAMB3 variant (c.-38+2 T>C) activates a cryptic splice site, causing 120 bp intronic inclusion in the 5'UTR; this creates upstream AUGs and uORFs and a more complex 5'UTR secondary structure, significantly reducing translation efficiency of LAMB3 without affecting overall mRNA levels, causing JEB.\",\n      \"method\": \"Whole-exome and whole-genome sequencing, luciferase translational efficiency assays, splice assay (minigene), in silico structural analysis, RT-PCR on patient gingival sample\",\n      \"journal\": \"Archives of oral biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — translational mechanism directly characterized by luciferase assay, splice mechanism by minigene assay, patient sample validation, multiple orthogonal methods\",\n      \"pmids\": [\"39357391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TGF-β secreted by hypoxic renal tubular epithelial cells activates canonical Smad signaling in fibroblasts, which upregulates LAMB3 expression via enhanced chromatin accessibility at the LAMB3 promoter; LAMB3 then initiates PI3K/AKT-dependent myofibroblast differentiation and renal fibrosis. Kidney-targeted knockdown of LAMB3 significantly ameliorates hypoxia-induced renal fibrosis in mice.\",\n      \"method\": \"ATAC-seq and RNA-seq (integrated), in vivo kidney-targeted LAMB3 knockdown, N-acetylcysteine (ROS scavenger) treatment, Western blot for Smad/AKT signaling, mouse hypoxic fibrosis model\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — chromatin accessibility at LAMB3 promoter by ATAC-seq, in vivo loss-of-function, multiple orthogonal methods\",\n      \"pmids\": [\"41412528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Ribosomal protein L35/uL29 (RpL35) ligands artesunate and atazanavir selectively increase production of full-length LAMB3 protein from PTC-containing mRNA via ribosome editing (targeted readthrough enhancement), producing up to 200% increase in full-length LAMB3 without affecting an unrelated PTC reporter.\",\n      \"method\": \"Dual luciferase reporter assays with LAMB3 PTC constructs vs. unrelated PTC reporter, drug treatment with artesunate and atazanavir\",\n      \"journal\": \"JID innovations\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assays demonstrating selective readthrough enhancement, selectivity confirmed by unrelated PTC control, single lab\",\n      \"pmids\": [\"38282649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SOX10 deficiency in MAPK inhibitor-resistant melanoma cells drives LAMB3 upregulation through TGF-β signaling; elevated LAMB3 activates integrin α3/α6 signaling and a FAK/MMPs axis to promote migration and invasion; LAMB3 depletion inhibits metastatic potential of MAPKi-resistant cells in a mouse lung metastasis model.\",\n      \"method\": \"Transcriptome profiling, Western blot, siRNA knockdown, migration/invasion assays, in vivo lung metastasis mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway dissection with knockdown and in vivo validation, single lab, multiple phenotypic readouts\",\n      \"pmids\": [\"38102338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Tumor-derived LAMB3 promotes LRRC15+ fibroblast differentiation in PDAC through the ITGB1/FAK/MAPK signaling axis, leading to FOSL2-dependent transcriptional activation of LRRC15 in fibroblasts and suppression of T cell cytotoxicity; FAK inhibition partially reverses these effects and LAMB3 knockdown improves PD-1 blockade efficacy.\",\n      \"method\": \"Single-cell atlas, functional assays (overexpression/knockdown), orthotopic mouse models, FAK inhibition, ChIP/transcriptome analysis for FOSL2-LRRC15\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined signaling axis with pharmacological and genetic validation in vivo, single study\",\n      \"pmids\": [\"42154006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"LAMB3 overexpression in keratinocytes upregulates cytokeratin expression and accelerates wound healing in vivo; the LAMB3-ITGA6 axis coordinates epithelial adhesion (hemidesmosome-associated gene activation) and keratinization in gingival epithelial repair, with retinoic acid reciprocally regulating this axis.\",\n      \"method\": \"Single-cell RNA sequencing, LAMB3 knockdown and overexpression (lentivirus), phalloidin staining, in vivo mouse dorsal wound healing model, retinol/BMS493 treatment\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain/loss-of-function with defined in vivo wound healing phenotype, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"41960183\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LAMB3 encodes the β3 subunit of the heterotrimeric extracellular matrix protein laminin 332 (laminin 5); it is essential for laminin 332 trimer assembly with LAMA3 and LAMC2 subunits, and the assembled complex mediates epidermal-dermal adhesion by anchoring hemidesmosomes to the basement membrane. Loss-of-function mutations cause junctional epidermolysis bullosa and/or amelogenesis imperfecta. LAMB3 expression is transcriptionally regulated by TGF-β, by the BRD2/acetylated-ELK4 complex, by NF-κB (P65), by FOXQ1 (stabilized by PARP1), and epigenetically by promoter methylation/H3K4me3; its mRNA stability is enhanced by NAT10-mediated N4-acetylation. In cancer contexts, LAMB3 activates downstream PI3K/AKT, FAK/ERK, c-MET/AKT, RhoA/ROCK1/MYL9, WNT/β-catenin, and NRF2 signaling pathways to drive cell proliferation, invasion, metastasis, chemoresistance, and immune suppression; it physically interacts with LAMC2 and ITGB4/MDFI, and is targeted post-transcriptionally by miR-1298, miR-24-3p, and miR-133a-2 via its 3'UTR.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"LAMB3 encodes the β3 chain of laminin 5/332, a basement-membrane component essential for dermal-epidermal adhesion and hemidesmosome assembly [#0, #5]. The β3 chain is a limiting subunit for laminin trimer assembly: it co-assembles with endogenous α3 and γ2 chains to deposit functional laminin in basement membranes, and restoring β3 alone is sufficient to rebuild laminin-332 and rescue adhesion phenotypes [#11, #16]. Loss-of-function mutations—nonsense, frameshift, splice-altering, and translation-reducing variants—abolish or attenuate laminin 332 and cause junctional epidermolysis bullosa, with milder hypomorphic alleles producing generalized atrophic benign EB [#0, #2, #6, #33]; β3 also functionally interacts with collagen XVII at the hemidesmosome anchoring complex, as shown by digenic JEB [#9]. Within the epithelium, LAMB3 engages integrin partners (notably ITGB4/α6β4 and ITGA6) to coordinate hemidesmosome formation, keratinization, and wound repair [#16, #38]. In cancer and fibrotic contexts, LAMB3 is markedly upregulated and signals through integrin-coupled FAK/ERK and PI3K/AKT cascades to drive proliferation, invasion, metastasis, EMT, chemoresistance, and immune suppression [#19, #27, #36, #37]; it physically associates with LAMC2 and with ITGB4/MDFI to propagate these signals [#22, #29]. Its expression is controlled at multiple levels: transcriptionally by TGF-β/Smad with promoter chromatin opening [#3, #34], by NF-κB(P65) [#24], by FOXQ1 [#28], and by the BRD2/acetylated-ELK4 complex [#20]; post-transcriptionally by NAT10-mediated ac4C mRNA stabilization [#27] and by 3'UTR-targeting microRNAs including miR-1298 and miR-24-3p [#15, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established LAMB3 as genetically essential for laminin 5 and skin adhesion by showing that nonsense mutations eliminate the protein and cause Herlitz JEB.\",\n      \"evidence\": \"Northern, RT-PCR, and sequencing of keratinocyte mRNA from H-JEB patients\",\n      \"pmids\": [\"7698759\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define how β3 assembles with partner chains\", \"No structural basis for adhesion loss\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined the complete LAMB3 gene structure, providing the framework to map and interpret JEB mutations.\",\n      \"evidence\": \"Sequencing of overlapping phage clones and exon-intron boundaries\",\n      \"pmids\": [\"7774918\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural map alone does not assign functional domains to phenotypes\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Linked specific short-arm domain VI mutations to milder GABEB and identified TGF-β as a non-coordinate inducer of LAMB3, opening regulatory study of the gene.\",\n      \"evidence\": \"Mutation analysis with EM/immunofluorescence; Northern hybridization after cytokine treatment of keratinocytes\",\n      \"pmids\": [\"7706760\", \"7635220\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"TGF-β transcriptional mechanism not resolved at this stage\", \"Domain VI interaction with laminin 6 inferred, not biochemically shown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Showed recurrent CpG nonsense mutations dominate the H-JEB mutational spectrum, explaining allele recurrence across families.\",\n      \"evidence\": \"PCR, restriction digestion, and haplotype analysis across 14 families\",\n      \"pmids\": [\"8824879\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address modifiers of phenotype severity\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Demonstrated that hypomorphic LAMB3 alleles (splice-altering missense, mRNA-destabilizing frameshift) produce reduced but partly functional laminin and milder disease, establishing a dosage/quality genotype-phenotype axis.\",\n      \"evidence\": \"RT-PCR splice analysis, mRNA decay assays, sequencing, and genotype-phenotype correlation across multiple patients\",\n      \"pmids\": [\"9501007\", \"9767254\", \"9690563\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative threshold of functional laminin needed for adhesion undefined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Provided in vivo loss-of-function proof that LamB3 is required for hemidesmosome ultrastructure via a mouse IAP-insertion model.\",\n      \"evidence\": \"Linkage, Northern, immunohistochemistry, and EM of mutant mouse skin\",\n      \"pmids\": [\"9271670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test which partner chain assembly step is rate-limiting\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Revealed functional interaction between LAMB3 and COL17A1 at the anchoring filament complex through digenic JEB.\",\n      \"evidence\": \"Mutation analysis, skin immunofluorescence, and hemidesmosome EM\",\n      \"pmids\": [\"10577906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical β3-collagen XVII contact not demonstrated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established β3 as the limiting subunit for laminin-5 trimer assembly by showing transgenic β3 co-assembles with endogenous α3/γ2 to rebuild basement-membrane laminin in deficient mice.\",\n      \"evidence\": \"Prenatal adenoviral/AAV LAMB3 delivery and immunohistochemical co-assembly assessment in H-JEB mice\",\n      \"pmids\": [\"16871230\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single study with partial rescue\", \"Stoichiometry of assembly not quantified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified epigenetic control of LAMB3 (promoter demethylation and H3K4me3) as a mechanism of its derepression in cancer.\",\n      \"evidence\": \"Methylation/expression profiling, H3K4me3 ChIP, and methylation-inhibitor treatment in gastric cancer cells\",\n      \"pmids\": [\"21345334\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the transcription factors recruited to the active promoter\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"First established a functional pro-invasive/metastatic role for LAMB3 in cancer through loss-of-function.\",\n      \"evidence\": \"siRNA/shRNA knockdown with invasion assays and in vivo metastasis models in lung cancer\",\n      \"pmids\": [\"23441154\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream signaling not yet mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Placed LAMB3 downstream of oncogenic KRAS as a synthetic-lethal node, linking it to FAK and to microRNA control.\",\n      \"evidence\": \"miR-TRAP target capture, knockdown, and rescue co-expression with in vivo tumor growth\",\n      \"pmids\": [\"27698189\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which LAMB3 sustains KRAS-driven survival not fully defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated functional therapeutic restoration of laminin 332 by nonsense readthrough and by monoallelic gene correction, reconstituting adhesion and integrin polarization.\",\n      \"evidence\": \"Gentamicin readthrough across 8 PTC constructs and CRISPR/Cas9 HDR correction, with 3D skin equivalents and in vivo grafting\",\n      \"pmids\": [\"29946029\", \"30122422\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Durability and efficiency of correction in patient tissue not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected LAMB3 to specific oncogenic signaling axes (c-MET/AKT-driven EMT) in epithelial cancer.\",\n      \"evidence\": \"siRNA knockdown with invasion assays and Western blot for EMT markers, AKT, and c-MET in thyroid cancer\",\n      \"pmids\": [\"29426928\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether c-MET is a direct LAMB3 effector unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed LAMB3 drives PDAC growth and metastasis via PI3K/AKT activation.\",\n      \"evidence\": \"siRNA knockdown, cell-cycle/apoptosis assays, xenograft and metastasis models, PI3K/AKT Western blot\",\n      \"pmids\": [\"30850586\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor coupling LAMB3 to PI3K/AKT not identified here\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined direct transcriptional and post-transcriptional regulators of LAMB3 in cancer and linked it to AKT-FOXO suppression.\",\n      \"evidence\": \"ChIP/luciferase/Co-IP for BRD2-ELK4 promoter binding with JQ1; dual-luciferase 3'UTR assay for miR-24-3p with rescue\",\n      \"pmids\": [\"32398865\", \"32039003\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of each regulator in vivo not weighted\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Confirmed direct LAMB3-LAMC2 physical interaction and identified additional upstream regulators (S100A10/JNK, PIGR-REST repression).\",\n      \"evidence\": \"Co-IP for LAMB3-LAMC2 and PIGR-REST, JNK inhibition, and rescue experiments in PDAC and CRC\",\n      \"pmids\": [\"36612197\", \"35992840\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab Co-IP without reciprocal structural validation\", \"Stoichiometry of LAMB3-LAMC2 in tumor context unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established NF-κB(P65) as a direct LAMB3 transcriptional activator and connected LAMB3 to integrin α3β1/FAK signaling in inflammation.\",\n      \"evidence\": \"Dual-luciferase, ChIP-PCR, RNA-seq, and NF-κB inhibitor treatment in intestinal inflammation\",\n      \"pmids\": [\"37454278\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the FAK output is identical across tissues not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Broadened LAMB3 signaling outputs to RhoA/ROCK1/MYL9 cytoskeletal remodeling, NRF2-dependent radioresistance, and integrin/FAK-driven metastasis in resistant melanoma.\",\n      \"evidence\": \"Gain/loss-of-function with pharmacological pathway manipulation in stromal cells, melanoma, and nasopharyngeal carcinoma, plus in vivo models\",\n      \"pmids\": [\"37801199\", \"36947579\", \"38102338\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"These context-specific axes share an upstream integrin step that is not directly compared\", \"Single lab per axis\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified a translation-level disease mechanism (uORF-creating 5'UTR variant) and a ribosome-editing therapeutic strategy for PTC alleles.\",\n      \"evidence\": \"Luciferase translation assays, minigene splicing, structural analysis, and RpL35-ligand readthrough reporter assays\",\n      \"pmids\": [\"39357391\", \"38282649\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Translational variant validated in reporter, not patient protein for the 5'UTR case\", \"Ribosome-editing selectivity tested only in reporters\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Resolved layered control and feedback of LAMB3 in cancer—NAT10 ac4C mRNA stabilization, FOXQ1/PARP1 transcriptional activation, YAP-TEAD4 feedback, MDFI/ITGB4 physical complex, and CRABP2 induction—each coupling LAMB3 to FAK/ERK, PI3K/AKT, MAPK, or WNT/β-catenin signaling and to immune suppression.\",\n      \"evidence\": \"acRIP, ChIP-seq/ChIP-PCR, Co-IP/MS, ubiquitination assays, RNA-seq, and in vivo tumor/immune models across PDAC, ovarian, CRC, and prostate cancer\",\n      \"pmids\": [\"40540648\", \"38297082\", \"39016677\", \"38375821\", \"39038078\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a secreted matrix subunit triggers PD-L1/immune programs mechanistically incomplete\", \"Most axes shown in one cancer type each\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended LAMB3 immunosuppressive and stromal functions to LAMB3-CXCL2-driven CAF infiltration and to ITGA6-coordinated epithelial repair, identifying druggable upstream regulators (melatonin, retinoic acid).\",\n      \"evidence\": \"RNA-seq, knockdown/overexpression, immune profiling, and in vivo models in TNBC and gingival/wound repair\",\n      \"pmids\": [\"39306019\", \"41960183\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect LAMB3 control of CXCL2 not dissected\", \"Single lab per system\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established LAMB3 as a profibrotic effector: TGF-β/Smad opens LAMB3 promoter chromatin to drive PI3K/AKT-dependent myofibroblast differentiation and renal fibrosis.\",\n      \"evidence\": \"Integrated ATAC-seq/RNA-seq, kidney-targeted LAMB3 knockdown, and Smad/AKT Western blot in a hypoxic fibrosis model\",\n      \"pmids\": [\"41412528\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether fibrosis depends on secreted laminin or intracellular signaling not separated\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Mapped a tumor-stroma circuit in which secreted LAMB3 drives LRRC15+ fibroblast differentiation via ITGB1/FAK/MAPK and FOSL2, suppressing T cells and limiting PD-1 blockade.\",\n      \"evidence\": \"Single-cell atlas, gain/loss-of-function, FAK inhibition, ChIP for FOSL2-LRRC15, and orthotopic immune-competent models\",\n      \"pmids\": [\"42154006\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor partner on fibroblasts not uniquely defined\", \"Single study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single matrix subunit switches between its structural adhesion role and a signaling/immunomodulatory role, and whether tumor effects require secreted laminin-332 assembly versus monomeric β3, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of β3 in tumor signaling complexes\", \"Direct receptor(s) coupling LAMB3 to PI3K/AKT vs FAK/ERK not unified\", \"Whether trimer assembly is required for oncogenic signaling untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 5, 11, 16]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [0, 5, 16]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 11, 16]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [11, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [0, 5, 11, 16]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [19, 24, 27, 36]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [16, 38]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 2, 9, 33]}\n    ],\n    \"complexes\": [\"laminin 332 (laminin 5)\", \"hemidesmosome anchoring filament complex\"],\n    \"partners\": [\"LAMC2\", \"ITGB4\", \"MDFI\", \"ITGA6\", \"COL17A1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}